(Q56048539)

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

The history of gold therapy for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

The history of gold therapy in rheumatoid disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Crystal Structure of the Antiarthritic Drug Gold Thiomalate (Myochrysine): A Double-Helical Geometry in the Solid State

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Chrysotherapy: a synoptic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold-based therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Anti-cancer potential of gold complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Developing new metal-based therapeutics: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

New trends for metal complexes with anticancer activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Metal based drugs: from serendipity to design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Inhibition of lysosomal cysteine proteases by a series of Au(I) complexes: a detailed mechanistic investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Inhibition of cathepsin B by Au(I) complexes: a kinetic and computational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Tuning the Au(I)-mediated inhibition of cathepsin B through ligand substitutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold(I)-mediated inhibition of protein tyrosine phosphatases: a detailed in vitro and cellular study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

The thioredoxin system—From science to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Thioredoxin reductase as a pathophysiological factor and drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Undressing of phosphine gold(I) complexes as irreversible inhibitors of human disulfide reductases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Interaction of gold(I) with the active site of selenium-glutathione peroxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

A gold(I) phosphine complex selectively induces apoptosis in breast cancer cells: implications for anticancer therapeutics targeted to mitochondria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Inhibition of selenium metabolism in the oral pathogen Treponema denticola

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold nanoparticles in biology: beyond toxicity to cellular imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Ludwig Mond Lecture. High-carat gold compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Theoretical chemistry of gold. III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold(I) efflux from auranofin-treated red blood cells. Evidence for a glutathione-gold-albumin metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Activation of gold-reactive T lymphocytes in rheumatoid arthritis patients treated with gold

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

The Antirheumatic Drug Gold, a Coin With Two Faces: AU(I) and AU(III). Desired and Undesired Effects on the Immune System

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

The mechanisms of action of disease-modifying antirheumatic drugs: a review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Molecular mechanisms of action of gold in treatment of rheumatoid arthritis--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Overexpression of thioredoxin reductase 1 regulates NF‐κB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Induction of cellular antioxidative stress genes through heterodimeric transcription factor Nrf2/small Maf by antirheumatic gold(I) compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

The Escherichia coli copper-responsive copA promoter is activated by gold.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold derivatives for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Synthesis, structure and cytotoxicity of triphenylphosphinegold(I) sulfanylpropenoates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

A gold(I) complex with a vitamin K3 derivative: characterization and antitumoral activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Novel gold(I) 7-azacoumarin complex: synthesis, structure, optical properties, and cytotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

A gold(I) phosphine complex containing a naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Inhibitory effects of a new oral gold compound on hela cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

A sugar-modified phosphole gold complex with antiproliferative properties acting as a thioredoxin reductase inhibitor in MCF-7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold(I) complexes determine apoptosis with limited oxidative stress in Jurkat T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Cytotoxicity and antitumor activity of some tetrahedral bis(diphosphino)gold(I) chelates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

In vivo and in vitro cardiotoxicity of a gold-containing antineoplastic drug candidate in the rabbit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Mitochondrial Membrane Potential in Living Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Role of lipophilicity in determining cellular uptake and antitumour activity of gold phosphine complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

In vitro antitumour and hepatotoxicity profiles of Au(I) and Ag(I) bidentate pyridyl phosphine complexes and relationships to cellular uptake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold(I) chloride adducts of 1,3-bis(di-2-pyridylphosphino)propane: synthesis, structural studies and antitumour activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Antitumor activity of the mixed phosphine gold species chlorotriphenylphosphine-1,3-bis(diphenylphosphino)propanegold(I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Mitochondria are primary targets in apoptosis induced by the mixed phosphine gold species chlorotriphenylphosphine-1,3-bis(diphenylphosphino)propanegold(I) in melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Chemical behavior and in vitro activity of mixed phosphine gold(I) compounds on melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

In vitro and in vivo antitumor properties of tetrakis((trishydroxy- methyl)phosphine)gold(I) chloride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Synthesis, structure and cytotoxicity studies of diisopropylammonium and triethylammonium salts of triphenylphosphinegold(I) sulfanylcarboxylates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Cationic, linear Au(I) N-heterocyclic carbene complexes: synthesis, structure and anti-mitochondrial activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Solution chemistry and cytotoxic properties of novel organogold(III) compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Structural characterization, solution studies, and DFT calculations on a series of binuclear gold(III) oxo complexes: relationships to biological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold(III) compounds of 1,4,7-triazacyclononane showing high cytotoxicity against A-549 and HCT-116 tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Anticancer cyclometalated [Au(III)m(C(wedge)N(wedge)C)mL]n+ compounds: Synthesis and cytotoxic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Mechanisms of cytotoxicity of selected organogold(III) compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

DNA binding properties of novel cytotoxic gold(III) complexes of terpyridine ligands: the impact of steric and electrostatic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Proteomic characterization of the cytotoxic mechanism of gold (III) porphyrin 1a, a potential anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Modulation of gold(III) porphyrin 1a-induced apoptosis by mitogen-activated protein kinase signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Thioredoxin reductase and cancer cell growth inhibition by organogold(III) compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Metal compounds for the treatment of parasitic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

21 January 2018

New uses for old drugs

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Aurothiomalate Inhibits Transformed Growth by Targeting the PB1 Domain of Protein Kinase Cι

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Gold(III) Porphyrin 1a Induced Apoptosis by Mitochondrial Death Pathways Related to Reactive Oxygen Species

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: Results of the METGO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7

Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F9783527633104.CH7